Viking治療 VKTX 深 滬
等待開盤 09-30 09:30:00 美东时间
25.81
+0.240
+0.94%
華盛通- 最 高26.46
- 今 開25.55
- 成交量 398.26万股
- 最 低 25.29
- 昨 收 25.57
- 總市值 28.91亿
- 52周最高 81.7295
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 18.92
- 委 比 48.43%
- 總股本 1.12亿
- 歷史最高 99.41
- 量 比 0.76
- 振 幅 4.58%
- 歷史最低 0.88
- 每 手 1
- 風險率 13.91%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 潜在涨幅207.38%！GoldMining获HC Wainwright升目标价至3.75美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持GoldMining"买入"评级，目标价从3.25美元升至3.75美元；摩根士丹利：维持Crinetics Pharmaceuticals"超配"评级，目标价从65美元升至77美元
38分钟前
HC Wainwright & Co. Reiterates Buy on Viking Therapeutics, Maintains $102 Price Target
HC Wainwright & Co. analyst Joseph Pantginis reiterates Viking Therapeutics (NASDAQ: VKTX) with a Buy and maintains $102 price target.
09-29 22:38
美股大行评级 | 潜在涨幅1650.0%！Ascendiant Capital维持GRI Bio"买入"评级，目标价上调至35美元
今日重点评级关注：Ascendiant Capital：维持GRI Bio"买入"评级，目标价从34美元升至35美元；Ascendiant Capital：维持Atossa Therapeutics"买入"评级，目标价从7.5美元升至7.75美元
09-23 09:52
6 Health Care Stocks Whale Activity In Today's Session
This whale alert can help traders discover the next big trading opportunities. ...
09-23 01:35
BTIG Reiterates Buy on Viking Therapeutics, Maintains $125 Price Target
BTIG analyst Justin Zelin reiterates Viking Therapeutics (NASDAQ:VKTX) with a Buy and maintains $125 price target.
09-22 22:26
SA Asks: Which biotechs could be acquired by year's end?
The fourth quarter has historically been a busy time for the biopharma industry, with the sector generally seeing a significant uptick in M&A activity. We asked Seeking Alpha analysts Stephen Ayers ...
09-14 04:18
Peering Into Viking Therapeutics's Recent Short Interest
Viking Therapeutics's (NYSE:VKTX) short percent of float has fallen 4.11% since...
09-10 02:00
FDA Launches Green List To Protect Americans From Illegal Imported GLP-1 Drug Ingredients
https://www.fda.gov/news-events/press-announcements/fda-launches-green-list-protect-americans-illegal-imported-glp-1-drug-ingredients
09-05 23:40
Jim Cramer Expects Palantir To Reach New All-Time High
Market analysts and financial commentators provide crucial guidance in the volatile investment landscape. Cramer says no to VKTX, but expects PLTR to go up.
09-05 19:59
MASH drug developers rise as FDA accepts lenient trial requirement
Drug developers with products targeting a liver condition called metabolic dysfunction-associated steatohepatitis (MASH) traded higher on Wednesday after the U.S. FDA said it has accepted an easy-to-m...
08-28 01:44
